Scholar
Marketplace
Lab
Feedback
$
English
Sign In
Home
Search
My boards
Insights
Collaborators
Reader
Blog
Help
Home
Search
My boards
Insights
Collaborators
Reader
Blog
Help
KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients.
Translate
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bengali
Bosnian
Български
Catalan
Cebuano
中文(简体)
中文(繁體)
Corsican
Czech
Danish
Dutch
English
Esperanto
Estonian
Finnish
Français
Georgian
Deutsch
Greek
Haitian Creole
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Kazakh
Khmer
Korean
Kyrgyz
Lao
Latin
Latvian
Lithuanian
Luxembourgish
Macedonian
Malay
Maltese
Maori
Mongolian
Myanmar (Burmese)
Nepali
Norwegian
Pashto
Persian
Polish
Portuguese
Romanian
Russian
Samoan
Serbian
Sinhala
Slovak
Slovenian
Somali
Spanish
Swahili
Swedish
Tajik
Tamil
Thai
Turkish
Ukrainian
Urdu
Uzbek
Vietnamese
Xhosa
Zulu
Phouthone Keohavong
Stephanie Land
Autumn Gaither-Davis
Jill M Siegfried
Neil Christie
+4 authors
Journal:
2017/August
-
Molecular Carcinogenesis
ISSN:
1098-2744
PUBMED:
27182622
DOI:
10.1002/mc.22501
Abstract:
Mutations in the KRAS and TP53 genes have been found frequently in lung tumors and specimens from individuals at high risk for lung cancer and have been suggested as predictive markers for lung cancer. In order to assess the prognostic value of these two genes' mutations in lung cancer recurrence, we analyzed mutations in codon 12 of the KRAS gene and in hotspot codons of the TP53 gene in 176 bronchial biopsies obtained from 77 former lung cancer patients. Forty-seven patients (61.0%) showed mutations, including 35/77 (45.5%) in the KRAS gene and 25/77 (32.5%) in the TP53 gene, among them 13/77 (16.9%) had mutations in both genes. When grouped according to past or current smoking status, a higher proportion of current smokers showed mutations, in particular those in the TP53 gene (P = 0.07), compared with ex-smokers. These mutations were found in both abnormal lesions (8/20 or 40%) and histologically normal tissues (70/156 or 44.9%) (P = 0.812). They consisted primarily of G to A transition and G to T transversion in both the KRAS (41/56 or 73.2%) and TP53 (24/34 or 70.6%) genes, consistent with mutations found in lung tumors of smoking lung cancer patients. Overall, recurrence-free survival (RFS) among all subjects could be explained by age at diagnosis, tumor stage, tumor subtype, and smoking (P < 0.05, Cox proportional hazard). Therefore, KRAS and TP53 mutations were frequently detected in bronchial tissues of former lung cancer patients. However, the presence of mutation of bronchial biopsies was not significantly associated with a shorter RFS time. © 2016 Wiley Periodicals, Inc.
Open in
PUBMED
|
DOI
|
Google Scholar
|
Wikipedia
Relations:
Citations
(2)
Diseases
(1)
Conditions
(1)
Chemicals
(2)
Genes
(2)
Organisms
(1)
Processes
(1)
Anatomy
(1)
Affiliates
(3)
Similar articles
Articles by the same authors
Discussion board
Collaboration tool especially designed for Life Science professionals.
Drag-and-drop any entity to your messages.
Learn More
Search and select entities to see details here. Details will include lists of related entities (via publication). Explore related entities further.
Learn More